Zobrazeno 1 - 10 of 18 pro vyhledávání: '"Terri A Binder"'
1
Akademický článek
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers
Autor: Aurélien Marabelle, Aung Naing, Funda Meric-Bernstam, Xingfeng Bao, Andrea Varga, David S Hong, Aparna Parikh, Geoffrey I Shapiro, Özlem Ataman, Larisa Reyderman, Terri A Binder, Min Ren, Mingjie Liu, Satish Dayal, Amy Y Siu, Pallavi Sachdev, Lucy Xu, Vijay Bhagawati-Prasad, Ilian Tchakov, Chean Eng Ooi
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background E7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune microenvironment. This first-in-human phase 1 study assessed the safet
Externí odkaz: https://doaj.org/article/e224332c09c046d89e9e666fa3f6b4e3
Zobrazit plný text záznamu
2
Akademický článek
Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day
Autor: Matthew H. Taylor, Sophie Leboulleux, Yury Panaseykin, Bhavana Konda, Christelle de LaFouchardiere, Brett G. M. Hughes, Andrew G. Gianoukakis, Young Joo Park, Ilia Romanov, Monika K. Krzyzanowska, Diana Garbinsky, Bintu Sherif, Jie Janice Pan, Terri A. Binder, Nicholas Sauter, Ran Xie, Marcia S. Brose
Publikováno v: Cancer Medicine, Vol 12, Iss 4, Pp 4332-4342 (2023)
Abstract Background In the phase 2 double‐blind Study 211, a starting dose of lenvatinib 18 mg/day was compared with the approved starting dose of 24 mg/day in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC). Predefi
Externí odkaz: https://doaj.org/article/dc0ec1a8bab345c086c5e789e1eef9a5
Zobrazit plný text záznamu
4
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial
Autor: Sumanta K. Pal, Javier Puente, Daniel Y.C. Heng, Hilary Glen, Piotr Koralewski, Daniil Stroyakovskiy, Boris Alekseev, Francis Parnis, Daniel Castellano, Tudor Ciuleanu, Jae Lyun Lee, Kaisa Sunela, Karen O'Hara, Terri A. Binder, Lixian Peng, Alan D. Smith, Sun Young Rha
Publikováno v: European urology. 82(3)
Background: Lenvatinib (18 mg) plus everolimus (5 mg) is approved for patients with advanced renal cell carcinoma (RCC) after one or more prior antiangiogenic therapies. Objective: To assess whether a lower starting dose of lenvatinib has comparable
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb02af5394bc353a869121863019a156
https://pubmed.ncbi.nlm.nih.gov/35577645
Zobrazit plný text záznamu
5
A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
Autor: Ran Xie, Matthew H. Taylor, Young Joo Park, Sophie Leboulleux, Andrew G. Gianoukakis, Corina E. Dutcus, Monika K. Krzyzanowska, Bhavana Konda, Brett G.M. Hughes, Terri A. Binder, Marcia S. Brose, Ilia Romanov, Christelle De La Fouchardiere, Yury Panaseykin
Publikováno v: The Journal of clinical endocrinology and metabolism. 107(3)
Background Lenvatinib is a multikinase inhibitor approved to treat radioiodine-refractory differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day. This study explored, in a double-blinded fashion, whether a starting dose of 18 mg/day w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc897d160cfabebea63a8f48effffb6e
https://pubmed.ncbi.nlm.nih.gov/34664662
Zobrazit plný text záznamu
6
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE
Autor: David S, Hong, Aparna, Parikh, Geoffrey I, Shapiro, Andrea, Varga, Aung, Naing, Funda, Meric-Bernstam, Özlem, Ataman, Larisa, Reyderman, Terri A, Binder, Min, Ren, Mingjie, Liu, Satish, Dayal, Amy Y, Siu, Pallavi, Sachdev, Lucy, Xu, Vijay, Bhagawati-Prasad, Ilian, Tchakov, Chean Eng, Ooi, Xingfeng, Bao, Aurelien, Marabelle
Publikováno v: Journal for Immunotherapy of Cancer
Background E7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune microenvironment. This first-in-human phase 1 study assessed the safet
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::145fdac8f1ef2ea42f708c1157066faa
https://pubmed.ncbi.nlm.nih.gov/32554609
Zobrazit plný text záznamu
10
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers
Autor: Pallavi Sachdev, Amy Siu, Xingfeng Bao, Geoffrey I. Shapiro, Aung Naing, Vijay Bhagawati-Prasad, O. Ataman, Aurélien Marabelle, Lucy Xu, David S. Hong, Larisa Reyderman, Terri A. Binder, Satish Dayal, Andrea Varga, Aparna Raj Parikh, Mingjie Liu, Funda Meric-Bernstam, Ilian Tchakov, Min Ren, Chean Eng Ooi
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundE7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune microenvironment. This first-in-human phase 1 study assessed the safety
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a926ef25c1c8bbba411f7030246ddd5b
https://doi.org/10.1136/jitc-2019-000222
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje